Wednesday 13 September 2017

Immunotheraphy combo

Do you have any experience or thoughts about this study?
http://www.practiceupdate.com/c/57122/67/12/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_braincancer&elsca4=braincancer&elsca5=newsletter&rid=MjMxMDE2NzMzNjcyS0&lid=10332481

Has anyone tried this combo?
Best wishes to all
Brainbutton

2 comments:

  1. CTLA-4 and PD-1 antibodies (namely ipilimumab/Yervoy, nivolumab/Opdivo, and pembrolizumab/Keytruda) are approved drugs. Though not approved yet for GBM, some have accessed these drugs in clinical trials or with off-label prescriptions.

    Genetically engineered herpes virus expressing IL-12 is not an approved drug, so the only way to access it would be in clinical trial. There's at least one such trial recruiting in the USA (recruitment temporarily suspended), but I haven't heard of any outcomes being published. This trial doesn't include checkpoint inhibitors, and its possible that the particular combo of CTLA-4, PD-1 antibodies and oHSV-IL-12 has not been studies in humans.
    https://clinicaltrials.gov/ct2/show/NCT02062827

    Other combination trials combining oncolytic virotherapy and checkpoint inhibitor antibodies are currently recruiting
    https://clinicaltrials.gov/ct2/show/NCT02798406

    I have high hopes for these combination therapies, but haven't heard of any publicized outcomes. The study above opened just over a year ago, so it may be a while yet before we see outcomes publicized (perhaps within the next few years, probably as an abstract at one of the big cancer meetings).

    ReplyDelete